These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 21270186

  • 1. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
    Besser RE, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT.
    Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
    [Abstract] [Full Text] [Related]

  • 2. Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes.
    Besser RE, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, Heywood JJ, Barrett TG, Hattersley AT.
    Pediatr Diabetes; 2013 May; 14(3):181-8. PubMed ID: 23289766
    [Abstract] [Full Text] [Related]

  • 3. Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
    Ozsu E, Cizmecioglu FM, Yesiltepe Mutlu G, Yuksel AB, Calıskan M, Yesilyurt A, Hatun S.
    Horm Res Paediatr; 2018 May; 90(4):257-265. PubMed ID: 30481753
    [Abstract] [Full Text] [Related]

  • 4. Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes.
    Wang Y, Gao Y, Cai X, Chen L, Zhou L, Ma Y, Gong S, Han X, Ji L.
    J Diabetes Res; 2019 May; 2019():1747684. PubMed ID: 31485449
    [Abstract] [Full Text] [Related]

  • 5. Urinary C-peptide creatinine ratio to differentiate type 2 diabetes mellitus from type 1 in pediatric patients.
    Elzahar W, Arafa A, Youssef A, Erfan A, El Amrousy D.
    Eur J Pediatr; 2020 Jul; 179(7):1115-1120. PubMed ID: 32052124
    [Abstract] [Full Text] [Related]

  • 6. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
    Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, Ellard S, Farmer AJ, McCarthy MI, Owen KR.
    Diabetes Care; 2012 Jun; 35(6):1206-12. PubMed ID: 22432108
    [Abstract] [Full Text] [Related]

  • 7. Urinary C-Peptide/Creatinine Ratio Can Distinguish Maturity-Onset Diabetes of the Young from Type 1 Diabetes in Children and Adolescents: A Single-Center Experience.
    Yılmaz Agladioglu S, Sagsak E, Aycan Z.
    Horm Res Paediatr; 2015 Jun; 84(1):54-61. PubMed ID: 25792383
    [Abstract] [Full Text] [Related]

  • 8. Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.
    Shields BM, Shepherd M, Hudson M, McDonald TJ, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson ER, Hattersley AT, UNITED study team.
    Diabetes Care; 2017 Aug; 40(8):1017-1025. PubMed ID: 28701371
    [Abstract] [Full Text] [Related]

  • 9. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH, Shields BM, Hudson M, Pearson ER, Hyde C, Ellard S, Hattersley AT, Patel KA, UNITED study.
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [Abstract] [Full Text] [Related]

  • 10. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
    Kyithar MP, Bonner C, Bacon S, Kilbride SM, Schmid J, Graf R, Prehn JH, Byrne MM.
    J Transl Med; 2013 Jun 26; 11():156. PubMed ID: 23803251
    [Abstract] [Full Text] [Related]

  • 11. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
    Ellard S, Colclough K.
    Hum Mutat; 2006 Sep 26; 27(9):854-69. PubMed ID: 16917892
    [Abstract] [Full Text] [Related]

  • 12. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
    McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S, Hattersley AT.
    Diabetes Care; 2011 Aug 26; 34(8):1860-2. PubMed ID: 21700917
    [Abstract] [Full Text] [Related]

  • 13. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
    Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gašperíková D, Szopa M, Tjora E, James TJ, Kokko P, Loiseleur F, Andersson E, Gaget S, Isomaa B, Nowak N, Raeder H, Stanik J, Njolstad PR, Malecki MT, Klimes I, Groop L, Pedersen O, Froguel P, McCarthy MI, Gloyn AL, Owen KR.
    Diabetologia; 2011 Nov 26; 54(11):2801-10. PubMed ID: 21814873
    [Abstract] [Full Text] [Related]

  • 14. Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes.
    Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, Oram RA, Knight B, Hyde C, Cox J, Mallam K, Moudiotis C, Smith R, Fraser B, Robertson S, Greene S, Ellard S, Pearson ER, Hattersley AT, UNITED Team.
    Diabetes Care; 2016 Nov 26; 39(11):1879-1888. PubMed ID: 27271189
    [Abstract] [Full Text] [Related]

  • 15. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.
    Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, Greenbaum CJ, Imperatore G, Lawrence JM, Marcovina SM, Mayer-Davis E, Rodriguez BL, Steck AK, Williams DE, Hattersley AT, SEARCH for Diabetes in Youth Study Group.
    J Clin Endocrinol Metab; 2013 Oct 26; 98(10):4055-62. PubMed ID: 23771925
    [Abstract] [Full Text] [Related]

  • 16. Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young.
    Wang X, Wang T, Yu M, Zhang H, Ping F, Zhang Q, Xu J, Feng K, Xiao X.
    Acta Diabetol; 2019 Mar 26; 56(3):281-288. PubMed ID: 30293189
    [Abstract] [Full Text] [Related]

  • 17. Mutations in HNF1A result in marked alterations of plasma glycan profile.
    Thanabalasingham G, Huffman JE, Kattla JJ, Novokmet M, Rudan I, Gloyn AL, Hayward C, Adamczyk B, Reynolds RM, Muzinic A, Hassanali N, Pucic M, Bennett AJ, Essafi A, Polasek O, Mughal SA, Redzic I, Primorac D, Zgaga L, Kolcic I, Hansen T, Gasperikova D, Tjora E, Strachan MW, Nielsen T, Stanik J, Klimes I, Pedersen OB, Njølstad PR, Wild SH, Gyllensten U, Gornik O, Wilson JF, Hastie ND, Campbell H, McCarthy MI, Rudd PM, Owen KR, Lauc G, Wright AF.
    Diabetes; 2013 Apr 26; 62(4):1329-37. PubMed ID: 23274891
    [Abstract] [Full Text] [Related]

  • 18. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection.
    Ekholm E, Shaat N, Holst JJ.
    Acta Diabetol; 2012 Oct 26; 49(5):349-54. PubMed ID: 21761282
    [Abstract] [Full Text] [Related]

  • 19. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
    Mughal SA, Park R, Nowak N, Gloyn AL, Karpe F, Matile H, Malecki MT, McCarthy MI, Stoffel M, Owen KR.
    Diabet Med; 2013 Feb 26; 30(2):246-50. PubMed ID: 23157689
    [Abstract] [Full Text] [Related]

  • 20. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
    Kyithar MP, Bacon S, Pannu KK, Rizvi SR, Colclough K, Ellard S, Byrne MM.
    Diabetes Metab; 2011 Dec 26; 37(6):512-9. PubMed ID: 21683639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.